The short version of reconstitution fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-04. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Similar effects are known for related androgenic progestins like medroxyprogesterone acetate and megestrol acetate. CPA has also been reported to lower HDL cholesterol levels, another effect associated with androgens. Accordingly, CPA shows weak androgenic effects in the liver in rodents which can be blocked by flutamide.
Robert Allan Humphreys (1930–1988), known as Laud Humphreys, was an American sociologist and Episcopal priest. He is noted for his research into sexual encounters between men in public bathrooms, published as Tearoom Trade (1970), and for the questions that emerged regarding the ethical nature of his research methods. He influenced generations of scholars who research issues related to sexuality and sexual identity.
under the joint auspices of the George Washington University and the Carnegie Institution of Washington. There, the news on nuclear fission was spread even further, which fostered many more experimental demonstrations. The 6 January 1939 Hahn and Strassman paper announced the discovery of fission. In their second publication on nuclear fission in February 1939, Hahn and Strassmann used the term Uranspaltung (uranium fission) for the first time, and predicted the existence and liberation of additional neutrons during the fission process, opening up the possibility of a nuclear chain reaction. The 11 February 1939 paper by Meitner and Frisch compared the process to the division of a liquid drop and estimated the energy released at 200 MeV. The 1 September 1939 paper by Bohr and Wheeler used this liquid drop model to quantify fission details, including the energy released, estimated the cross section for neutron-induced fission, and deduced 235U was the major contributor to that cross section and slow-neutron fission.
== Function == The product of this gene, P2Y1 belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor functions as a receptor for extracellular ATP and ADP. In platelets binding to ADP leads to mobilization of intracellular calcium ions via activation of phospholipase C, a change in platelet shape, and probably to platelet aggregation.
Beginning in the 1970s, research was initiated to address sources of indoor radon, determinants of concentration, health effects, and mitigation approaches. In the US, the problem of indoor radon received widespread publicity and intensified investigation after a widely publicized incident in 1984. During routine monitoring at a Pennsylvania nuclear power plant, a worker was found to be contaminated with radioactivity. A high concentration of radon in his home was subsequently identified as responsible.
Sources: en.wikipedia.org
Concussion-induced unconsciousness Cerebral ischemia Memory disruption Narcolepsy and cataplexy Seizures and spontaneous convulsions Spinal trauma In human studies, a 0.5 mg dose administered over 14 days improved consciousness in 73% of patients with neurological disturbances. Its ability to stimulate cholinergic and noradrenergic systems suggests promise in treating cognitive dysfunction and sleep disorders. Although it the patent, it said that the strength of the medicine was 4mg per tablet, but in contrast to TRH it can be administered orally and is more resistant to metabolic degradation.
There is extensive experience, over many years, of the use of radioiodine in the treatment of thyroid overactivity, and this experience does not indicate any increased risk of thyroid cancer following treatment. However, a study from 2007 has reported an increased number of cancer cases after radioiodine treatment for hyperthyroidism. The principal advantage of radioiodine treatment for hyperthyroidism is that it tends to have a much higher success rate than medications. Depending on the dose of radioiodine chosen, and the disease under treatment (Graves' vs. toxic goiter, vs. hot nodule, etc.), the success rate in achieving definitive resolution of the hyperthyroidism may vary from 75 to 100%. A major expected side-effect of radioiodine in people with Graves' disease is the development of lifelong hypothyroidism, requiring daily treatment with thyroid hormone. On occasion, some people may require more than one radioactive treatment, depending on the type of disease present, the size of the thyroid, and the initial dose administered. People with Graves' disease manifesting moderate or severe Graves' ophthalmopathy are cautioned against radioactive iodine-131 treatment, since it has been shown to exacerbate existing thyroid eye disease. People with mild or no ophthalmic symptoms can mitigate their risk with a concurrent six-week course of prednisone. The mechanisms proposed for this side effect involve a TSH receptor common to both thyrocytes and retro-orbital tissue.
Nakamoto limited the block size to one megabyte. The limited block size and frequency can lead to delayed processing of transactions, increased fees and a bitcoin scalability problem. The Lightning Network, a second-layer routing network, is a potential scaling solution. Research shows a trend towards centralization in bitcoin as miners join pools for stable income. If a single miner or pool controls more than 50% of the hashing power, it would allow them to censor transactions and double-spend coins. In 2014, mining pool Ghash.io reached 51% mining power, causing safety concerns, but later voluntarily capped its power at 39.99% for the benefit of the whole network. A few entities also dominate other parts of the ecosystem such as the client software, online wallets, and simplified payment verification (SPV) clients.
=== IR sources === FTIR spectrometers are mostly used for measurements in the mid and near IR regions. For the mid-IR region, 2−25 μm (5,000–400 cm−1), the most common source is a silicon carbide (SiC) element heated to about 1,200 K (930 °C; 1,700 °F) (Globar). The output is similar to a blackbody. Shorter wavelengths of the near-IR, 1−2.5 μm (10,000–4,000 cm−1), require a higher temperature source, typically a tungsten-halogen lamp. The long wavelength output of these is limited to about 5 μm (2,000 cm−1) by the absorption of the quartz envelope. For the far-IR, especially at wavelengths beyond 50 μm (200 cm−1) a mercury discharge lamp gives higher output than a thermal source.
Sources: en.wikipedia.org
== Rhenium-186 == Rhenium-186 is a low-energy beta emitter and radiopharmaceutical that is used to treat glioblastoma, is used in theranostic medicine and has been reported to be used in synoviorthesis. The maximum tissue penetration of 186Re is 4.5mm, making it a promising candidate for therapy of tumors with millimeter to centimeter dimensions. It also emits a low-abundance gamma ray with an energy of 137keV, which make it useful for SPECT dosimetry studies and in-vivo imaging of radio-labelled biomolecules. A radiopharmaceutical containing 186Re, tin, and HEDP was found to localize in painful skeletal metastasizes and ease pain for about 80% of patients.
{\displaystyle {\frac {d\eta }{dt}}=-\eta \nabla _{\text{h}}\cdot \mathbf {v} _{\text{h}}-\left({\frac {\partial w}{\partial x}}{\frac {\partial v}{\partial z}}-{\frac {\partial w}{\partial y}}{\frac {\partial u}{\partial z}}\right)-{\frac {1}{\rho ^{2}}}\mathbf {k} \cdot \left(\nabla _{\text{h}}p\times \nabla _{\text{h}}\rho \right)}
Over a 10-year period starting in 2008, Burger King predicted 80 percent of its market share would be driven by foreign expansion, particularly in the Asia-Pacific and Indian subcontinent regional markets. While the TPG-led group continued BK's international expansion by announcing plans to open new franchise locations in Eastern Europe, Africa and the Middle East, and Brazil, the company plan is focusing on the three largest markets – India, China, and Japan. The company plans to add over 250 stores in these Asian territories, as well as other places such as Macau, by the end of 2012. Its expansion into the Indian market has the company at a competitive disadvantage with other fast food restaurants such as KFC because of the aversion of the country's large Hindu majority to beef. BK hopes to use their non-beef products, such as their TenderCrisp and TenderGrill chicken sandwiches, as well as other products like mutton sandwiches and veggie sandwiches, to help them overcome this hurdle to expand in that country. 3G has reported that it will continue with the plans to grow globally, even ramping up the planned expansion to help increase their return on investment. It is expected that 3G Brazilian-based management connections in the region may help Burger King expand in Brazil and Latin America, where it has been having problems finding acceptable franchisees. In December 2020, Burger King India went in for an initial public offering (IPO) on the BSE and NSE in India. The IPO was subscribed over 150 times.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.